Ayanin, a non-selective phosphodiesterase 1-4 inhibitor, effectively suppresses ovalbumin-induced airway hyperresponsiveness without affecting xylazine/ketamine-induced anesthesia

Fei Peng Lee, Chwen Ming Shih, Hsin Y. Shen, Chien Ming Chen, Chi Ming Chen, Wun-Chang Ko

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In recent in vitro reports, the IC50 value of ayanin (quercetin-3,7,4′-O-trimethylether) was 2.2μM for inhibiting interleukin (IL)-4 production from purified basophils, and its therapeutic ratio was >19. Therefore, we were interested in investigating the effects on ovalbumin induced airway hyperresponsiveness in vivo, and to clarify its potential for treating asthma. Ayanin (30-100μmol/kg, orally (p.o.)) dose-dependently and significantly attenuated the enhanced pause (Penh) value induced by methacholine in sensitized and challenged mice. It also significantly suppressed the increases in total inflammatory cells, macrophages, lymphocytes, neutrophils, and eosinophils, and levels of cytokines, including IL-2, IL-4, IL-5, and tumor necrosis factor (TNF)-α in bronchoalveolar lavage fluid of these mice. However, at 100μmol/kg, it significantly enhanced the level of interferon (IFN)-γ. In addition, ayanin (30-100μmol/kg, p.o.) dose-dependently and significantly suppressed total and OVA-specific immunoglobulin (Ig)E levels in the serum and bronchoalveolar lavage fluid, and enhanced the IgG2a level in serum of these mice. In the present results, ayanin did not affect xylazine/ketamine-induced anesthesia, suggesting that ayanin has few or no adverse effects, such as nausea, vomiting, and gastric hypersecretion. In conclusion, the above results suggest that ayanin may have the potential for use in treating allergic asthma.

Original languageEnglish
Pages (from-to)198-203
Number of pages6
JournalEuropean Journal of Pharmacology
Volume635
Issue number1-3
DOIs
Publication statusPublished - Jun 2010

Fingerprint

Phosphodiesterase 4 Inhibitors
Xylazine
Ovalbumin
Ketamine
Anesthesia
Bronchoalveolar Lavage Fluid
Interleukin-4
Asthma
Basophils
Methacholine Chloride
Interleukin-5
Quercetin
Serum
Eosinophils
Nausea
Interferons
Immunoglobulin E
Inhibitory Concentration 50
Vomiting
Interleukin-2

Keywords

  • Airway hyperresponsiveness
  • Allergic asthma
  • Ayanin
  • Cytokine
  • PDE4/PDE4 ratio
  • Phosphodiesterase inhibitor

ASJC Scopus subject areas

  • Pharmacology

Cite this

Ayanin, a non-selective phosphodiesterase 1-4 inhibitor, effectively suppresses ovalbumin-induced airway hyperresponsiveness without affecting xylazine/ketamine-induced anesthesia. / Lee, Fei Peng; Shih, Chwen Ming; Shen, Hsin Y.; Chen, Chien Ming; Chen, Chi Ming; Ko, Wun-Chang.

In: European Journal of Pharmacology, Vol. 635, No. 1-3, 06.2010, p. 198-203.

Research output: Contribution to journalArticle

@article{a7a9b1c397124fdc9a9bcf461396db90,
title = "Ayanin, a non-selective phosphodiesterase 1-4 inhibitor, effectively suppresses ovalbumin-induced airway hyperresponsiveness without affecting xylazine/ketamine-induced anesthesia",
abstract = "In recent in vitro reports, the IC50 value of ayanin (quercetin-3,7,4′-O-trimethylether) was 2.2μM for inhibiting interleukin (IL)-4 production from purified basophils, and its therapeutic ratio was >19. Therefore, we were interested in investigating the effects on ovalbumin induced airway hyperresponsiveness in vivo, and to clarify its potential for treating asthma. Ayanin (30-100μmol/kg, orally (p.o.)) dose-dependently and significantly attenuated the enhanced pause (Penh) value induced by methacholine in sensitized and challenged mice. It also significantly suppressed the increases in total inflammatory cells, macrophages, lymphocytes, neutrophils, and eosinophils, and levels of cytokines, including IL-2, IL-4, IL-5, and tumor necrosis factor (TNF)-α in bronchoalveolar lavage fluid of these mice. However, at 100μmol/kg, it significantly enhanced the level of interferon (IFN)-γ. In addition, ayanin (30-100μmol/kg, p.o.) dose-dependently and significantly suppressed total and OVA-specific immunoglobulin (Ig)E levels in the serum and bronchoalveolar lavage fluid, and enhanced the IgG2a level in serum of these mice. In the present results, ayanin did not affect xylazine/ketamine-induced anesthesia, suggesting that ayanin has few or no adverse effects, such as nausea, vomiting, and gastric hypersecretion. In conclusion, the above results suggest that ayanin may have the potential for use in treating allergic asthma.",
keywords = "Airway hyperresponsiveness, Allergic asthma, Ayanin, Cytokine, PDE4/PDE4 ratio, Phosphodiesterase inhibitor",
author = "Lee, {Fei Peng} and Shih, {Chwen Ming} and Shen, {Hsin Y.} and Chen, {Chien Ming} and Chen, {Chi Ming} and Wun-Chang Ko",
year = "2010",
month = "6",
doi = "10.1016/j.ejphar.2010.02.055",
language = "English",
volume = "635",
pages = "198--203",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Ayanin, a non-selective phosphodiesterase 1-4 inhibitor, effectively suppresses ovalbumin-induced airway hyperresponsiveness without affecting xylazine/ketamine-induced anesthesia

AU - Lee, Fei Peng

AU - Shih, Chwen Ming

AU - Shen, Hsin Y.

AU - Chen, Chien Ming

AU - Chen, Chi Ming

AU - Ko, Wun-Chang

PY - 2010/6

Y1 - 2010/6

N2 - In recent in vitro reports, the IC50 value of ayanin (quercetin-3,7,4′-O-trimethylether) was 2.2μM for inhibiting interleukin (IL)-4 production from purified basophils, and its therapeutic ratio was >19. Therefore, we were interested in investigating the effects on ovalbumin induced airway hyperresponsiveness in vivo, and to clarify its potential for treating asthma. Ayanin (30-100μmol/kg, orally (p.o.)) dose-dependently and significantly attenuated the enhanced pause (Penh) value induced by methacholine in sensitized and challenged mice. It also significantly suppressed the increases in total inflammatory cells, macrophages, lymphocytes, neutrophils, and eosinophils, and levels of cytokines, including IL-2, IL-4, IL-5, and tumor necrosis factor (TNF)-α in bronchoalveolar lavage fluid of these mice. However, at 100μmol/kg, it significantly enhanced the level of interferon (IFN)-γ. In addition, ayanin (30-100μmol/kg, p.o.) dose-dependently and significantly suppressed total and OVA-specific immunoglobulin (Ig)E levels in the serum and bronchoalveolar lavage fluid, and enhanced the IgG2a level in serum of these mice. In the present results, ayanin did not affect xylazine/ketamine-induced anesthesia, suggesting that ayanin has few or no adverse effects, such as nausea, vomiting, and gastric hypersecretion. In conclusion, the above results suggest that ayanin may have the potential for use in treating allergic asthma.

AB - In recent in vitro reports, the IC50 value of ayanin (quercetin-3,7,4′-O-trimethylether) was 2.2μM for inhibiting interleukin (IL)-4 production from purified basophils, and its therapeutic ratio was >19. Therefore, we were interested in investigating the effects on ovalbumin induced airway hyperresponsiveness in vivo, and to clarify its potential for treating asthma. Ayanin (30-100μmol/kg, orally (p.o.)) dose-dependently and significantly attenuated the enhanced pause (Penh) value induced by methacholine in sensitized and challenged mice. It also significantly suppressed the increases in total inflammatory cells, macrophages, lymphocytes, neutrophils, and eosinophils, and levels of cytokines, including IL-2, IL-4, IL-5, and tumor necrosis factor (TNF)-α in bronchoalveolar lavage fluid of these mice. However, at 100μmol/kg, it significantly enhanced the level of interferon (IFN)-γ. In addition, ayanin (30-100μmol/kg, p.o.) dose-dependently and significantly suppressed total and OVA-specific immunoglobulin (Ig)E levels in the serum and bronchoalveolar lavage fluid, and enhanced the IgG2a level in serum of these mice. In the present results, ayanin did not affect xylazine/ketamine-induced anesthesia, suggesting that ayanin has few or no adverse effects, such as nausea, vomiting, and gastric hypersecretion. In conclusion, the above results suggest that ayanin may have the potential for use in treating allergic asthma.

KW - Airway hyperresponsiveness

KW - Allergic asthma

KW - Ayanin

KW - Cytokine

KW - PDE4/PDE4 ratio

KW - Phosphodiesterase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=77952323268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952323268&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2010.02.055

DO - 10.1016/j.ejphar.2010.02.055

M3 - Article

C2 - 20307524

AN - SCOPUS:77952323268

VL - 635

SP - 198

EP - 203

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -